Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025
BioArctic AB (Nasdaq Stockholm: BIOA B) reported that its partner Eisai achieved Leqembi® sales of JPY 23.1 billion in Q2 2025. This generated royalty revenue of SEK 162.5 million for BioArctic, representing a 280% increase compared to Q2 2024.
The quarter's sales included a one-time stockpiling effect of JPY 5.3 billion in the Chinese market due to tariff risks. Excluding this effect, global sales were JPY 17.8 billion, corresponding to royalty revenue of approximately SEK 125 million.
BioArctic AB (Nasdaq Stoccolma: BIOA B) ha comunicato che il suo partner Eisai ha raggiunto vendite di Leqembi® per 23,1 miliardi di JPY nel secondo trimestre del 2025. Questo ha generato per BioArctic un ricavo da royalty di 162,5 milioni di SEK, pari a un aumento del 280% rispetto al secondo trimestre del 2024.
Le vendite del trimestre includono un effetto di accumulo una tantum di 5,3 miliardi di JPY nel mercato cinese dovuto ai rischi tariffari. Escludendo questo effetto, le vendite globali sono state di 17,8 miliardi di JPY, corrispondenti a un ricavo da royalty di circa 125 milioni di SEK.
BioArctic AB (Nasdaq Estocolmo: BIOA B) informó que su socio Eisai logró ventas de Leqembi® por 23,1 mil millones de JPY en el segundo trimestre de 2025. Esto generó para BioArctic unos ingresos por regalías de 162,5 millones de SEK, lo que representa un aumento del 280% en comparación con el segundo trimestre de 2024.
Las ventas del trimestre incluyeron un efecto puntual de acumulación de stock de 5,3 mil millones de JPY en el mercado chino debido a riesgos arancelarios. Excluyendo este efecto, las ventas globales fueron de 17,8 mil millones de JPY, lo que corresponde a ingresos por regalías de aproximadamente 125 millones de SEK.
BioArctic AB (나스닥 스톡홀름: BIOA B)는 파트너인 Eisai가 2025년 2분기에 Leqembi® 매출 231억 JPY를 달성했다고 보고했습니다. 이는 BioArctic에 1억 6,250만 SEK의 로열티 수익을 창출했으며, 2024년 2분기 대비 280% 증가한 수치입니다.
이번 분기 매출에는 관세 위험으로 인한 중국 시장에서의 일회성 재고 증가 효과 53억 JPY가 포함되어 있습니다. 이 효과를 제외하면 전 세계 매출은 178억 JPY로, 약 1억 2,500만 SEK의 로열티 수익에 해당합니다.
BioArctic AB (Nasdaq Stockholm : BIOA B) a annoncé que son partenaire Eisai a réalisé des ventes de Leqembi® de 23,1 milliards de JPY au deuxième trimestre 2025. Cela a généré pour BioArctic un revenu de redevances de 162,5 millions de SEK, soit une augmentation de 280 % par rapport au deuxième trimestre 2024.
Les ventes du trimestre comprenaient un effet ponctuel de constitution de stocks de 5,3 milliards de JPY sur le marché chinois en raison des risques tarifaires. En excluant cet effet, les ventes mondiales se sont élevées à 17,8 milliards de JPY, correspondant à un revenu de redevances d’environ 125 millions de SEK.
BioArctic AB (Nasdaq Stockholm: BIOA B) berichtete, dass sein Partner Eisai im zweiten Quartal 2025 Leqembi®-Verkäufe in Höhe von 23,1 Milliarden JPY erzielte. Dies generierte für BioArctic Lizenzgebührenerlöse von 162,5 Millionen SEK, was eine Steigerung von 280 % gegenüber dem zweiten Quartal 2024 darstellt.
Die Verkäufe des Quartals enthielten einen einmaligen Lageraufbaueffekt von 5,3 Milliarden JPY auf dem chinesischen Markt aufgrund von Zollrisiken. Ohne diesen Effekt lagen die weltweiten Verkäufe bei 17,8 Milliarden JPY, was Lizenzgebührenerlöse von etwa 125 Millionen SEK entspricht.
- Leqembi sales generated SEK 162.5 million in royalties, up 280% year-over-year
- Strong market performance with JPY 23.1 billion in total sales
- Successful penetration in Chinese market evidenced by stockpiling activity
- JPY 5.3 billion of sales attributed to one-time stockpiling effect, not recurring revenue
- Chinese market sales potentially affected by future tariff risks
The results included a one-time stockpiling effect in the Chinese market of around
BioArctic's report for the second quarter 2025 will be published on August 28 at 08:00 a.m. CET.
This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on July 31, 2025, at 12:00 CET.
For further information, please contact:
Oskar Bosson, VP Communications and Investor Relations
E-mail: oskar.bosson@bioarctic.com
Telephone: +46 704 107 180
About lecanemab (Leqembi®)
Lecanemab is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab is approved in 46 countries including the
Since July 2020, Eisai's Phase 3 clinical study (AHEAD 3-45) with lecanemab in individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. The study was fully recruited in October 2024. AHEAD 3-45 is a four-year study conducted as a public-private partnership between Eisai, Biogen and the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the
About the collaboration between BioArctic and Eisai
Since 2005, BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer's disease. The most important agreements are the Development and Commercialization Agreement for the lecanemab antibody, which was signed 2007, and the Development and Commercialization agreement for the antibody Leqembi back-up for Alzheimer's disease, which was signed 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer's disease. BioArctic has the right to commercialize lecanemab in the Nordic region and is currently preparing for commercialization in the Nordics together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer's disease and is entitled to payments in connection with sales milestones as well as royalties on global sales.
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Sales of Leqembi® totaled |
View original content:https://www.prnewswire.com/news-releases/sales-of-leqembi-totaled-23-1-billion-yen-in-the-second-quarter-2025--302518545.html
SOURCE BioArctic
FAQ
What were BioArctic's (BIOA) Leqembi royalty revenues in Q2 2025?
How much were Leqembi's global sales for BioArctic (BIOA) in Q2 2025?
What was the impact of Chinese stockpiling on BioArctic's (BIOA) Q2 2025 sales?
When will BioArctic (BIOA) release its full Q2 2025 financial results?
